Company intelligence / Profile preview
Aprin Sama Pharmed
- Ownership
- Private
- Development stage
- Other
01
Overview
Tilmanocept, a peptide-based radiopharmaceutical, completed preclinical studies and entered clinical trials in Iran, enabling affordable, accurate lymphatic mapping for cancer diagnosis and potentially improving lives for 90% of cancer patients in the region. Aprin Sama Pharmed is responsible for the manufacturing of peptide APIs and custom synthesis services
- Therapeutic areas
- Oncology
- Modalities
- PeptideNanoparticleRadiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Aprin Sama Pharmed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aprin Sama Pharmed.